Genomics in Scotland strategy: business and regulatory impact assessment

7. Competition Assessment

This strategy, which aims to improve the accessibility and availability of genomic testing in Scotland, should have no impact on the competitiveness of Scottish companies within the UK, in Europe or the rest of the world.

As no legislation or potentially limiting factors would be placed on the pharmaceutical industry, it is unlikely that there would be an impact on their competitiveness within the UK and global market.